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Obesity is a major risk factor for insulin resistance;
however, the factors linking these disorders are not
well defined. Herein, we show that the noninhibitory
serine protease inhibitor, pigment epithelium-derived
factor (PEDF), plays a causal role in insulin resis-
tance. Adipocyte PEDF expression and serum levels
are elevated in several rodent models of obesity and
reduced upon weight loss and insulin sensitization.
Leanmice injected with recombinant PEDF exhibited
reduced insulin sensitivity during hyperinsulinemic-
euglycemic clamps. Acute PEDF administration acti-
vated the proinflammatory serine/threonine kinases
c-Jun terminal kinase and extracellular regulated
kinase in both muscle and liver, which corresponded
with reduced insulin signal transduction. Prolonged
PEDF administration stimulated adipose tissue lipol-
ysis, resulted in ectopic lipid deposition, and reduced
insulin sensitivity, while neutralizing PEDF in obese
mice enhanced insulin sensitivity. Overall, these re-
sults identify a causal role for PEDF in obesity-
induced insulin resistance.
INTRODUCTION
The increased prevalence of obesity in industrialized countries is
closely associated with the development of chronic diseases
including atherosclerosis, nonalcoholic fatty liver disease, dyslipi-
demia,and type 2 diabetes (Wellenand Hotamisligil, 2005). Insulin
resistance is a central feature of the pathophysiology of most
obesity-related disorders including type 2 diabetes, and is de-
fined as a subnormal response of tissues to the actions of insulin.
Several possible mediators of insulin resistance in obesity,
including dysregulation of lipid metabolism (Savage et al., 2007)
and low-grade inflammation (Wellen and Hotamisligil, 2005),
have been identified. However, the mechanistic link between
these parameters is not understood.40 Cell Metabolism 10, 40–47, July 8, 2009 ª2009 Elsevier Inc.Adipocytes are known to regulate whole-body metabolism, at
least in part via the release of secretory or endocrine factors such
as leptin (Halaas et al., 1995) and adiponectin (Maeda et al.,
2002). Modifications in the secretion of several adipocyte
secreted factors contributes to dysregulation of metabolism
either via central or peripheral effects (Rosen and Spiegelman,
2006). This has led to major investigation of adipose secretory
factors in the hope of identifying other regulatory molecules
that might play other as-yet-unidentified roles in whole-body
metabolism. One of the limitations with many studies in this
area is that the contribution of adipose tissue secretion to circu-
lating levels of such factors is not clear, and in some cases it
remains controversial if adipocytes per se are the source of the
secretory factor, as opposed to nonparenchymal cells such as
endothelial cells.
In the present studies we identify the serine protease inhibitor
(serpin), pigment epithelium-derived factor (PEDF, SerpinF1) as
a bona fide adipocyte secretory factor. This is an exciting obser-
vation as circulating PEDF was recently found to be upregulated
in individuals with the metabolic syndrome (Yamagishi et al.,
2006) and patients with type 2 diabetes mellitus (Jenkins et al.,
2008; Ogata et al., 2007). PEDF is a multifunctional protein that
promotes neuronal survival and differentiation and possesses
anti-angiogenic activities (Tombran-Tink and Barnstable, 2003).
It is a unique serpin because its c-reactive loop is inactive and is
thereby noninhibitory, meaning that it does not directly inhibit
serine proteases or other serpin targets such as caspases. In
this way, PEDF may provide a link between obesity and insulin
resistance. Using a range of physiological methods, we provide
causal evidence in favor of this claim.
RESULTS
Identification of the Adipocyte Secretome by Mass
Spectrometry
Previous efforts to identify the secretome of adipocytes have
included the use of a signal sequence trap cloning procedure
and proteomics. In the case of proteomics, media is usually
collected from cells grown in culture; proteins are concentrated
and then sequenced using mass spectrometry. A major
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PEDF Causes Insulin ResistanceFigure 1. PEDF Is Elevated in Obesity and Reduced by Weight Loss
(A) Plasma PEDF concentrations in mice fed a control (chow) and high-fat diet (HFD) for 12 weeks.
(B–D) PEDF mRNA in the adipocyte and stomal vascular fraction (SVF), (C) PEDF protein expression, and (D) PEDF release from epididymal adipose tissue of mice
after chow and HFD.
(E and F) PEDF mRNA and (F) protein in obese ob/ob mice and lean littermates.
(G) PEDF mRNA content in mice fed a HFD or mice that lost15% of their body mass by 7 day ciliary neurotrophic factor (CNTF) administration or caloric restric-
tion (low-calorie diet). n = 8 mice for all groups; error bars are ± SEM; *p < 0.05 versus group with open bars.limitation is the presence of contaminants in the media due to cell
surface shedding or cellular lysis and release of intracellular
content. To circumvent these limitations, we have implemented
a lectin affinity chromatography step to enrich for glycoproteins
prior to mass spectrometry on the assumption that many, but not
all, secretory proteins undergo complex N-linked glycosylation
prior to release. Using this method, we screened conditioned
media from 3T3-L1 adipocytes. One of the most abundant
proteins identified in this screen based upon peptide coverage
in the mass spectrum (20.6% of the full-length protein detected)
was PEDF. While PEDF has been implicated as an important
metabolic regulatory secretory factor, little is known of its mech-
anism of action.
Adipose Tissue and Plasma PEDF Levels Are Elevated
in Obesity
We initially examined plasma PEDF levels in obesity. Mice were
fed a low-fat (chow, 4% fat) or high-fat (HFD, 60% fat) diet for
12 weeks. The high-fat diet resulted in elevated body mass
(chow, 28.9 ± 0.6 g versus HFD, 35.8 ± 1.2 g) and adipose tissue
mass (epididymal fat pad, chow: 335 ± 29 mg versus HFD: 1439 ±
192 mg). Mice fed a HFD were mildly hyperglycaemic (blood
glucose: chow, 8.8 ± 0.4 mM versus HFD, 10.2 ± 0.9 mM) and
hyperinsulinemic (plasma insulin: chow, 49 ± 6 pM versus HFD,
107 ± 21 pM), suggestive of insulin resistance. The plasma
PEDF concentration averaged 4.9 ± 1.6 ng/ml for chow andwas increased 3.2-fold by HFD (Figure 1A). A similar increase in
the PEDF mRNA (Figure 1B) and protein-expression levels
(Figure 1C) in adipose tissue was also observed in HFD mice.
PEDF expression was increased in both the adipocyte and
stromal vascular fraction of adipose tissue (Figure 1B), and
most of the whole-tissue increase was attributable to enhanced
adipocyte expression. Ex vivo analysis revealed that adipose
tissue PEDF secretion was greater in obese versus lean mice
(Figure 1D), supporting a link between adipose tissue PEDF
production and plasma levels. While PEDF was readily detected
as an adipose secretory factor, only modest PEDF secretion was
detected in cultured hepatocytes and myocytes and in whole
mouse liver and skeletal muscle incubated ex vivo for 5 hr in
oxygenated Krebs buffer (data not shown). This is intriguing
because this pattern does not correspond to the relative tissue-
specific expression profile of PEDF (Figure S1). This suggests
that adipocytes likely make an important contribution to circu-
lating levels of this factor. The level of the PEDF mRNA and
protein was also increased in the adipose tissue of obese, lep-
tin-deficient ob/ob mice compared with lean littermate controls
(Figures 1E and 1F). There was no striking effect of obesity on
skeletal muscle or liver PEDF expression (Figure S2). We then as-
sessed the effects of weight loss on adipose PEDF expression in
obese mice using either caloric restriction or ciliary neurotrophic
factor administration as described previously (Crowe et al.,
2008). PEDF mRNA expression was decreased by 2.1- andCell Metabolism 10, 40–47, July 8, 2009 ª2009 Elsevier Inc. 41
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PEDF Causes Insulin ResistanceFigure 2. Acute PEDF Administration Causes Insulin Resistance in Skeletal Muscle and Liver
(A) 2-deoxyglucose uptake experiments in EDL muscles isolated from C57Bl/6 mice. Muscles were pretreated without (open bars) or with (closed bars) 100 nM
PEDF for 2 hr. The media was removed and basal and insulin stimulated 2DG uptake determined. n = 8 EDL muscles from independent mice for each group. *p <
0.05 versus basal within the same treatment; #p < 0.05 versus PEDF insulin treatment. Values are means ± SEM.
(B) Plasma PEDF concentrations 2 hr after C57Bl/6 mice were injected with saline (open bars) or PEDF (closed bars) in the intraperotineal cavity. *p < 0.05 versus
saline; n = 8 mice for each group.
(C and D) Insulin tolerance tests and (D) glucose tolerance tests 2 hr after C57Bl/6 mice were injected with saline (open bars) or PEDF (closed bars) in the intra-
perotineal cavity. n = 6 mice for each group; *p < 0.05 versus saline.
(E–G) Direct measures of insulin sensitivity by hyperinsulinemic-euglycemic clamp after PEDF injection. Lean C57Bl/6 mice aged 10 weeks were injected with
PEDF 2.5 h prior to clamps where whole-body glucose infusion rate (E), glucose disposal rate (F), and hepatic glucose production (G) were determined. *p <
0.05 versus vehicle; n = 8 mice for each group.
(H) Phosphorylation of the serine/threonine kinases ERK, JNK, and IKK-b in skeletal muscle at the end of the hyperinsulinemic-euglycemic clamp. (n = 8 per
group); *p < 0.05 versus vehicle.
(I and J) Insulin signaling in muscle (I) and liver (J) at the end of the hyperinsulinemic-euglycemic clamp. n = 8 per group; *p < 0.05 versus vehicle; error bars are ±
SEM.5.4-fold, respectively, compared with mice fed a HFD (Figure 2F).
Together, these data show that circulating levels of PEDF as well
as its expression in adipose tissue correlates very well with
whole-body adiposity and insulin sensitivity.
PEDF Regulates GlucoseMetabolism in Skeletal Muscle
and Liver
To determine whether PEDF directly regulates skeletal muscle
insulin sensitivity, we treated isolated EDL muscles from lean
mice with recombinant PEDF for 2 hr and assessed 2-deoxy-
D-glucose (2DG) uptake. PEDF did not affect basal 2DG uptake
but reduced insulin-stimulated 2DG disposal by 30%42 Cell Metabolism 10, 40–47, July 8, 2009 ª2009 Elsevier Inc.(Figure 2A). The specific effect of PEDF on skeletal muscle
glucose uptake was also verified in L6 myotubes (Figure S3)
and was maintained for 24 hr (data not shown). To test whether
these effects could be recapitulated in vivo, lean mice were in-
jected with 50 mg PEDF 2 hr prior to an insulin tolerance test
(ITT), resulting in an increase in circulating PEDF levels from
3.8 ± 1.2 ng/ml to 12.4 ± 3.1 ng/ml (Figure 2B). These levels
are similar to those observed in lean and obese mice, respec-
tively (Figure 1A). There was no change in basal plasma glucose
concentration following PEDF injection (saline: 6.9 ± 0.7 mM,
PEDF: 7.6 ± 0.5 mM, p = 0.45) whereas whole-body insulin sensi-
tivity was decreased (Figure 2C). Mice pretreated with PEDF also
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PEDF Causes Insulin ResistanceFigure 3. Prolonged PEDF Administration Mediates Insulin Resistance in Lean Mice
(A and B) Lean C57bl/6 mice were continuous infused with recombinant PEDF (closed bars) or sterile saline (open bars) for 5 days. Plasma glucose (A) and insulin
(B) were assessed in 4 hr fasted mice.
(C) Whole-body insulin sensitivity was assessed by ITT.
(D) Skeletal muscle 2DG uptake was assessed in EDL muscle ex vivo with or without the addition of 10 nM insulin. *p < 0.05 versus basal; #p < 0.05 versus control
insulin.
(E) Plasma FFA were assessed in 4 hr fasted mice.
(F and G) Skeletal muscle was removed and triglyceride (TG), diglyceride (DG) and ceramide assessed.
(H) Liver TG. *p < 0.05 versus control. For all experiments, n = 6 mice per group. Error bars are ± SEM.displayed impaired glucose tolerance (Figure 2D), independent
of changes in plasma insulin levels (Table S1). These effects of
PEDF raise the possibility that obesity-associated elevations in
PEDF might play a role in insulin resistance.
To investigate this further and to quantitatively examine the
contribution of liver and skeletal muscle to PEDF-induced insulin
resistance, we injected lean mice with PEDF 2.5 hr prior to hyper-
insulinemic-euglycemic clamps. There were no differences in
basal glucose turnover between vehicle (24 ± 1.6 mg/kg/min)
or PEDF (23 ± 0.8 mg/kg/min) treated mice; however, the amount
of exogenous glucose required to maintain euglycemia during
insulin stimulation was significantly diminished with prior PEDF
administration, indicating whole-body insulin resistance (Fig-
ure 2E). The insulin-stimulated glucose disposal rate, primarily
reflecting skeletal muscle glucose disposal, was decreased
with PEDF (Figure 2F). In addition, suppression of hepatic
glucose production was blunted in PEDF treated animals
(Figure 2G), as indicated by the increased rate of glucose
production by the liver during the clamp. It is unlikely that these
effects are due to changes in insulin secretion as plasma insulin
levels were identical between PEDF treated and control mice
during the hyperinsulinemic clamps. Moreover, basal plasma
insulin levels were not different 2 hr after PEDF injection or
following a glucose load (Table S1).
PEDF Induces Proinflammatory Signaling and Impairs
Insulin Signaling
We next sought to identify the mechanism for PEDF-induced
insulin resistance. PEDF induces proinflammatory signaling inseveral cell types (Tombran-Tink and Barnstable, 2003), which
is of interest in view of the possible role of inflammation in insulin
resistance (Aguirre et al., 2000; Bost et al., 2005; Gao et al.,
2002). PEDF was associated with a decrease in phospho-ERK
and phospho-JNK in skeletal muscle (Figure 2H) and liver (not
shown), concomitant with a reduction in the insulin-dependent
activation of insulin receptor substrate-1 and Akt, as indicated
by reduced phosphorylation at their activating sites (Figures 2I
and 2J) during the hyperinsulinemic-euglycemic clamp studies.
Similar effects were observed in cultured myotubes (Figure S4).
Importantly, serine/threonine kinase activation and impaired
insulin signal transduction occurred independent of changes in
other known mediators of insulin resistance including bioactive
lipid metabolite accumulation and endoplasmic reticulum stress
(data not shown).
Prolonged PEDF Administration in Lean Mice Causes
Ectopic Lipid Deposition and Insulin Resistance
To explore the effect of prolonged PEDF administration in vivo,
miniosmotic pumps were surgically implanted into lean C57Bl/
6 mice. PEDF was continuously infused for 5 days as validated
and described previously (Apte et al., 2004). Fasting plasma
glucose and insulin were unaffected by PEDF (Figures 3A and
3B), whereas whole-body insulin sensitivity (Figure 3C) and
insulin-stimulated glucose uptake into skeletal muscle were
reduced (Figure 3D).
Obesity is characterized by excessive basal adipose tissue
lipolysis and increased postabsorptive circulating fatty acid
levels (Horowitz et al., 1999; Wolfe et al., 1987) that in turnCell Metabolism 10, 40–47, July 8, 2009 ª2009 Elsevier Inc. 43
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PEDF Causes Insulin ResistanceFigure 4. PEDF Neutralization in Obese, Insulin-Resistant Mice Improves Insulin Sensitivity
(A–D) Miniosmotic pumps were placed in obese mice and saline or PEDF-neutralizing antibody was infused for 5 days. Plasma glucose (A), insulin (B), and FFA (D)
were assessed in 4 hr fasted mice. In (C), mice were fasted for 4 hr and insulin tolerance tests were performed. n = 6 mice per group; *p < 0.05 main effect for
treatment.
(E–H) Skeletal muscle and liver lipids are decreased with PEDF neutralizing antibody treatment. Skeletal muscle triglyceride (E; TG), diglyceride (F; DG), and
ceramide (G), and liver TG (H) were assessed. n = 5 mice per group; p < 0.05 versus vehicle; error bars are ± SEM.contribute to the development of ectopic lipid deposition and
insulin resistance (Boden and Chen, 1995). We next explored
the role of PEDF in lipid metabolism by examining its effects on
adipose tissue lipolysis. As shown in Figure S5A, PEDF acutely
increased lipolysis in cultured 3T3-L1 adipocytes and in mice
in vivo as assessed by plasma glycerol and FFA levels (byprod-
ucts of triacylglycerol lipolysis) (Figure S4b). Plasma FFA levels
were increased following prolonged in vivo PEDF administration
(15%, p = 0.13; Figure 3E) coupled with an increase in muscle
lipid storage (Figures 3F and 3G). Liver TG was elevated by
66% in animals treated with PEDF (Figure 3H). Together, these
data support two possible mechanisms for PEDF-induced
insulin resistance, via stress signaling events in the short term
(Figures 2A–2J) and via lipid deposition in skeletal muscle and
liver in the longer term.
PEDF Neutralization in Obese, Insulin-Resistant Mice
Improves Insulin Sensitivity
We next tested whether blocking PEDF action could restore
insulin sensitivity in obese mice. Miniosmotic pumps were im-
planted into obese C57Bl/6 mice (mass: 36.1 ± 0.5 g) and
neutralizing PEDF antibody or control solution was continuously
infused for 5 days (Apte et al., 2004). The PEDF neutralizing anti-
body did not affect fasting blood glucose (Figure 4A) and insulin
levels (Figure 4B) but did improve whole-body insulin sensitivity
in these obese mice (Figure 4C), independent of changes in body
mass and adiposity (Table S2). Consistent with this notion,
parallel studies in cultured myotubes showed that adipocyte
conditioned media containing PEDF caused insulin resistance,
whereas coincubation with the PEDF-neutralizing antibody
largely restored insulin action (Figure S6).44 Cell Metabolism 10, 40–47, July 8, 2009 ª2009 Elsevier Inc.Sequestering fatty acids in adipocytes and/or reducing
adipose tissue lipolysis reduces fatty acid delivery to nonadipose
tissues such as skeletal muscle and liver, thereby limiting the
progression of insulin resistance (Bajaj et al., 2005; Unger,
2003). It is believed that this effect is mediated, in part, by mini-
mizing the accumulation of bioactive lipid metabolites known to
cause insulin resistance (Holland et al., 2007; Yu et al., 2002).
Plasma FFA was reduced with PEDF antibody administration
(Figure 4D), suggesting an inhibition of adipose tissue lipolysis.
Skeletal muscle triacylglycerol and diacylglycerol contents
were reduced with PEDF antibody administration (Figures 4E
and 4F). Furthermore, liver triacylglycerol (Figure 4I), diacylgly-
cerol and ceramide (Figure S7) levels were also reduced with
PEDF neutralizing antibody treatment. These data demonstrate
that reducing PEDF action in vivo restores insulin action in the
context of obesity. The reduction in circulating FFA and muscle
and liver lipid accumulation may have been one mechanism
underlying this insulin-sensitizing effect of PEDF neutralization
obesity.
DISCUSSION
Changes in fat-cell size are accompanied by reprogramming of
the fat-cell secretory profile, and this is thought to play an impor-
tant role in the link between obesity and insulin resistance (Guil-
herme et al., 2008; Tilg and Moschen, 2006). In this study, we
describe a role for a novel adipokine, PEDF, in whole-body
metabolism. Expression of PEDF in adipose tissue and plasma
levels of PEDF positively correlate with obesity and insulin resis-
tance. This is consistent with studies reporting a significant
correlation between plasma PEDF and adiposity in humans
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PEDF Causes Insulin Resistance(Jenkins et al., 2008; Yamagishi et al., 2006). To test the relation-
ship between circulating PEDF and insulin resistance, we admin-
istered either PEDF or PEDF-neutralizing antibodies to mice and
showed that this was accompanied by reduced or enhanced
whole-body insulin sensitivity, respectively. These studies there-
fore provide novel insights into yet another factor secreted from
adipose tissue that appears to play a key role in regulating
whole-body metabolism.
The mechanism by which PEDF induces insulin resistance is
not fully resolved. In addition to its role in neurogenesis and
angiogenesis, PEDF induces inflammatory signaling in several
cell types (Filleur et al., 2009) and circulating PEDF levels corre-
late with inflammation in individuals with type 1 diabetes (Jenkins
et al., 2007). Obesity triggers a low-grade inflammatory state that
results from the excessive release of proinflammatory cytokines
and chemokines from adipocytes and activated macrophages
that surround necrotic adipocytes (Cinti et al., 2005; Lumeng
et al., 2007). This inflammatory stress activates several serine/
threonine signaling molecules including IKKb, JNK, and ERK
that in turn inhibit downstream insulin signal transduction. The
importance of both JNK and IKK to the etiology of insulin resis-
tance is highlighted by the consistent observations that the
global (Hirosumi et al., 2002; Yuan et al., 2001) or tissue-specific
deletion of these stress kinases markedly improves insulin sensi-
tivity and glucose homeostasis in genetically obese (ob/ob) and
high-fat fed mice (Arkan et al., 2005; Sabio et al., 2008; Solinas
et al., 2007). Consistent with this notion, we show that PEDF
directly activates several proinflammatory signaling proteins in
skeletal muscle and liver in vivo, which is associated with
reduced insulin signal transduction. These effects occur within
30 min of PEDF administration, and prior to the upregulation of
other known mediators of insulin resistance including lipid
metabolite accumulation and ER stress induction.
The ‘‘lipocentric’’ view of insulin-resistance development
suggests that obesity is characterized by elevated basal adipose
tissue lipolysis (Langin et al., 2005) and greater systemic FFA
availability (Horowitz et al., 1999) that in turn contribute to exces-
sive ectopic lipid deposition and the development of insulin
resistance (Holland et al., 2007; Schmitz-Peiffer et al., 1999; Yu
et al., 2002). A striking observation in this study was that several
of these metabolic events were recapitulated with PEDF treat-
ment in lean mice. We show that PEDF can cause diabetogenic
effects indirectly through stimulation of adipocyte lipolysis and
subsequent ectopic diacylglycerol and ceramide deposition in
insulin-sensitive tissues. These events were reversed with
PEDF neutralization in obese, insulin-resistant mice. Taken
together, our studies indicate that PEDF can induce insulin resis-
tance through several mechanisms, including acute activation of
serine/threonine kinases known to impair insulin signal transduc-
tion and by altering systemic lipid metabolism that results in
ectopic tissue lipid deposition. This dual effect is reminiscent
of other adipokines known to cause insulin resistance. For
example, tumor necrosis factor (TNF) a, resistin, and inter-
leukin-6 are all capable of inducing serine/threonine kinase acti-
vation and lipolysis (Ort et al., 2005; Ryden and Arner, 2007).
Interestingly, PEDF appears to rapidly induce lipolytic stimula-
tion by interacting directly with the key lipolytic protein adipose
triglyceride lipase (Chung et al., 2008), while other adipokines
such as TNFa act more slowly (Plomgaard et al., 2008), presum-ably by modifying translational control of lipid droplet associated
proteins such as perilipin A (Ryden and Arner, 2007). Evidently,
other factors are likely to contribute to PEDF-induced insulin
resistance and will require further detailed analysis. More defin-
itive elucidation of PEDF interactions with its putative receptors
and high-affinity ligands (Filleur et al., 2009) will further assist in
deciphering the biological roles of PEDF.
An important question raised by these experiments is, why do
adipocytes secrete PEDF in obesity? In light of PEDFs powerful
anti-angiogenic function, there is good reason to assume that
PEDF is secreted to act as a brake on excessive vascularization
during adipocyte expansion. Adipocytes and stromal vascular
cells produce multiple angiogenic factors including leptin,
platelet derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), fibroblast growth factor (FGF)-2, trans-
forming growth factor (TGF)-b, and TNFa that contribute to
adipose neovascularisation, which is undoubtedly an essential
process for adipose tissue development (Cao, 2007). Precursor
fibroblasts, which exist to expand adipose tissue depots,
produce these proangiogenic factors, and their production is
downregulated during adipogenesis (Figure S8A). Meanwhile,
the anti-angiogenic PEDF is upregulated during adipogenesis
and is mostly produced by mature adipocytes (Figure S8B). It
is likely then that anti-angiogenic factors are secreted by mature
adipocytes to restrict excessive vascularization and maintain
homeostasis during adipose tissue growth. Indeed, a number
of angiogenesis inhibitors including thrombospondin 1, soluble
VEGFR2, and endostatin are produced in overweight or obese
humans (Silha et al., 2005; Voros et al., 2005). Both the observa-
tions reported here and previously (Yamagishi et al., 2006)
suggest that PEDF can be added to this list and supports the
premise that the net balance between proangiogenic factors
secreted from fibroblasts and anti-angiogenic factors secreted
from mature adipocytes is important for appropriate vasculariza-
tion during white adipose-tissue development (Cao, 2007).
In conclusion, we have identified a novel role for PEDF as
a negative regulator of insulin action in obesity. Given the observa-
tion that PEDF is increased in obese type 2 diabetic humans
(Jenkins et al., 2008; Yamagishi et al., 2006), therapeutic strate-
gies to inhibit PEDF action in muscle and liver, or prevent adipo-
cyte PEDF release, may prove a viable approach to ameliorate
obesity-induced insulin resistance and itsassociated pathologies.
EXPERIMENTAL PROCEDURES
Production of Recombinant PEDF
Recombinant PEDF was purified from a HEK293 cell line stably transfected
with human PEDF (Duh et al., 2002), and bioactivity was assessed by prolifer-
ation assay of SaOS-2 osteosarcoma cells.
Animal Maintenance and Experimental Protocols
Experimental procedures were approved by the St. Vincent’s Hospital Animal
Experimentation Ethics Committee, the School of Biomedical Sciences Animal
Ethics Committee (Monash University), and the Committee on Animal Re-
search at the University of California, Los Angeles. Eight-week-old male
C57Bl/6J mice (Monash Animal Services; Victoria, Australia) were fed a stan-
dard chow diet or a high-fat diet (60% calories from fat) for 16 weeks. Mice
were fasted for 4 hr prior to all experiments. See the Supplemental Experi-
mental Procedures for details of ex vivo, GTT, and ITT experiments. Metabolic
monitoring was performed in a Comprehensive Lab Animal Monitoring System
(Columbus Instruments; Columbus, OH).Cell Metabolism 10, 40–47, July 8, 2009 ª2009 Elsevier Inc. 45
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Glucose clamp studies were performed on 16-week-old normal chow-fed
C57Bl/6J mice (Jackson Laboratory) 3 days after chronic cannulation as previ-
ously described (Hevener et al., 2003) and detailed in SI methods.
Glucose Uptake
2DG uptake was measured by adding2-deoxy-D-[1,3H] glucose (1 mM,0.5mCi /
ml) and D-[1-14C]mannitol (8 mM, 0.2 mCi /ml) (Amersham Biosciences) to
Krebs buffer and is outlined in the Supplemental Experimental Procedures.
Plasma Hormone and Metabolite Analysis
PEDF was analyzed by ELISA for mouse PEDF (Chemicon, Temecula, CA).
Plasma glucose was assessed by a glucose oxidase method (Sigma), FFA
by an enzymatic colorimetric method (Wako), and insulin by RIA.
ConA Affinity Chromatography and Mass Spectrometry
3T3-L1 adipocytes were washed in PBS, once in serum-free DMEM, and left
overnight serum-free DMEM supplemented with 100 nM insulin. Conditioned
medium was collected, pooled, and dialyzed overnight with a 3000 MW cut-
off membrane. Concanavalin A sepharose 4B (GE Healthcare 17-0440-03)
was added and left to mix overnight. Glycoproteins were eluted and proteins
precipitated, resuspended in Laemmle buffer, and separated on SDS-PAGE
gels. Lanes were excised, dehydrated, and digested with trypsin. Peptides
were separated by liquid chromatography and subjected to tandem mass
spectrometry on a Waters Ultima quadruple time of flight (QTOF) mass spec-
trometer, as described previously (Larance et al., 2005).
qRT-PCR
Total RNA was extracted, reverse transcribed and quantitative PCR was per-
formed as described (Steinberg et al., 2007). PEDF and 18S primers were
purchased from Applied Biosystems.
Immunoblot Analysis
Immunoblotting was performed antibodies against IRS1, IRS-1 Y20, Akt, Akt
S473, Akt T308, phosphor- and total ERK1/2, JNK1/2, and IKK-b from Cell
Signaling (Danvers, MA), a-actin (Sigma), tubulin (Sigma T9026), IRS1 Y612
(Biosource; Carlsbad, CA) and PEDF (Duh et al., 2002). Immunofluorescence
analysis is detailed in the Supplemental Experimental Procedures.
Muscle Lipids
Muscle lipids were extracted in chloroform: methanol. TG was assessed by
measuring glycerol after saponification and DG and ceramide were measured
by a radiometric method as described (Watt et al., 2006).
Statistical Analysis
Statistical analysis was performed using unpaired Student’s t test. A two-way
ANOVA with repeated measures was applied where appropriate and a Student
Newman-Keuls post hoc analysis performed. Statistical significance was set
at p < 0.05.
SUPPLEMENTAL DATA
The Supplemental Data include eight figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://www.cell.com/cellmetabolism/supplemental/
S1550-4131(09)00159-4.
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